Olfactory ensheathing cells -LRB- OECs -RRB-	1
Olfactory ensheathing cells	1
OECs	30
neurocan in injured spinal cord	44
neurocan	44
injured spinal cord	56
matrix metalloproteinase-2	89
a rat contusion model Yui , Sho	119
a rat contusion model	119
Yui , Sho	142
Fujita , Naoki	152
Fujita	152
Naoki	160
Chung , Cheng-Shu	167
Chung	167
Cheng-Shu	174
Morita , Maresuke	185
Morita	185
Maresuke	193
Nishimura , Ryohei Abstract The mechanism	203
Nishimura , Ryohei Abstract The	203
mechanism	235
olfactory ensheathing cells -LRB- OECs -RRB-	254
olfactory ensheathing cells	254
OECs	283
functional recovery	322
transplantation	348
spinal cord injury -LRB- SCI -RRB-	369
spinal cord injury	369
SCI	389
the relevance of matrix metalloproteinases -LRB- MMPs -RRB-	430
the relevance	430
matrix metalloproteinases -LRB- MMPs -RRB-	447
matrix metalloproteinases	447
MMPs	474
We	500
the expression of MMPs	513
the expression	513
MMPs	531
OECs	539
the MMP secretion	557
OECs transplanted in injured spinal cord in vivo using a rat SCI model	578
OECs	578
injured spinal cord in vivo	599
injured spinal cord	599
vivo	622
a rat SCI model	633
We	650
the degradation	668
neurocan , which is one of the axon-inhibitory chondroitin sulfate proteoglycans	687
neurocan	687
one of the axon-inhibitory chondroitin sulfate proteoglycans	706
one	706
the axon-inhibitory chondroitin sulfate proteoglycans	713
SCI model rats	774
The	790
results	803
MMP-2	823
the dominant MMP expressed by OECs	833
the dominant MMP	833
OECs	863
The in vivo	869
The	869
vivo	876
transplanted OECs	903
MMP-2 in injured spinal cord	930
MMP-2	930
injured spinal cord	939
the expression of neurocan	968
the expression	968
neurocan	986
the transplantation of OECs	1026
the transplantation	1026
OECs	1049
These results	1055
OECs	1082
injured spinal cord degraded neurocan by secreting MMP-2	1105
injured spinal cord	1105
neurocan	1134
MMP-2	1156
Introduction Severe spinal cord injury -LRB- SCI -RRB-	1164
Introduction Severe spinal cord injury	1164
SCI	1204
traffic accidents or intervertebral disc diseases	1216
traffic accidents	1216
intervertebral disc diseases	1237
dogs9 ,11,15	1290
Patients with severe SCI	1304
Patients	1304
severe SCI	1318
irreversible quadriplegia or paraplegia and incontinence	1341
various clinical trials for SCI patients	1408
various clinical trials	1408
SCI patients	1436
a definitive treatment	1470
Cell transplantation therapy	1519
promising results	1584
Many types of cells	1623
Many types	1623
cells	1637
these studies	1664
embryonic stem cells , mesenchymal stem cells , neural stem and progenitor cells	1689
embryonic stem cells	1689
mesenchymal stem cells	1711
neural stem	1735
progenitor cells	1751
pluripotent stem cells6	1781
,23	1804
Olfactory ensheathing cells -LRB- OECs -RRB-	1812
Olfactory ensheathing cells	1812
OECs	1841
a promising candidate for cell transplantation therapy in SCI	1870
a promising candidate	1870
cell transplantation therapy in SCI	1896
cell transplantation therapy	1896
SCI	1928
OECs	1933
specific glial cells in the olfactory system	1942
specific glial cells	1942
the olfactory system	1966
they	1992
the notable ability to support axonal regeneration	2002
axonal regeneration	2033
A number of studies	2054
A number	2054
studies	2066
functional recovery	2088
OEC transplantation in SCI models2	2126
OEC transplantation	2126
SCI models2	2149
,7,13,17,19,25,27,28	2160
most	2192
these studies centered on the evaluation of functional recovery	2200
these studies	2200
the evaluation of functional recovery	2226
the evaluation	2226
functional recovery	2244
the mechanisms	2269
the functional recovery achieved with OEC transplantation	2295
the functional recovery	2295
OEC transplantation	2333
detail	2383
several mechanisms	2400
axonal regeneration by secreting neurotrophic factor4 -RRB-	2449
axonal regeneration	2449
neurotrophic factor4	2482
neurotrophic	2482
factor4	2495
remyelination of demyelinated axons2 ,7,18,19 -RRB-	2505
remyelination	2505
axons2 ,7,18,19	2535
axons2	2535
,7,18,19	2541
the protection of axons	2556
the protection	2556
axons	2574
that	2580
injury27	2594
no research	2605
a definite answer	2631
this question	2652
The irreversibility of SCI	2667
The irreversibility	2667
SCI	2690
chondroitin sulfate proteoglycans	2725
CSPGs	2760
these	2768
functional recovery from SCI	2782
functional recovery	2782
SCI	2807
axonal regeneration	2825
the injured spinal cord3 ,16,29	2848
the injured spinal cord3	2848
,16,29	2872
CSPGs	2881
several species	2895
an inhibitory effect on axonal regeneration	2916
an inhibitory effect	2916
axonal regeneration	2940
brevican , versican , neurocan , NG2 , and phosphacan8 ,12,20 -RRB-	2982
brevican , versican , neurocan , NG2 ,	2982
phosphacan8 ,12,20	3021
these five species	3044
neurocan	3064
the major inhibitory CSPG in SCI1	3102
the major inhibitory CSPG	3102
SCI1	3131
The degradation of CSPGs , especially neurocan ,	3138
The degradation	3138
CSPGs	3157
functional recovery	3194
rodent SCI models3	3217
,30	3235
The relevance of OECs and the degradation of CSPGs	3241
The relevance	3241
OECs and the degradation of CSPGs	3258
OECs	3258
the degradation of CSPGs	3267
the degradation	3267
CSPGs	3286
2006	3309
by Pastrana et al. 26	3314
Pastrana	3317
et al. 26	3326
et al.	3326
26	3332
They	3337
the mRNA expressions of matrix metalloproteinase-2 -LRB- MMP-2 -RRB-	3355
the mRNA expressions	3355
matrix metalloproteinase-2 -LRB- MMP-2 -RRB-	3379
matrix metalloproteinase-2	3379
MMP-2	3407
-9	3418
OECs	3433
they	3443
MMP-2	3460
the axonal regeneration of retinal neurons in vitro26 -RRB-	3475
the axonal regeneration	3475
retinal neurons	3502
vitro26	3521
MMPs	3531
a family of endopeptidases that contain Zn2 ＋ in the catalytic domain	3540
a family	3540
endopeptidases that contain Zn2 ＋ in the catalytic domain	3552
endopeptidases	3552
Zn2 ＋ in the catalytic domain	3580
Zn2 ＋	3580
the catalytic domain	3588
their main role in a living organism	3610
their main role	3610
a living organism	3629
the modulation of the extracellular matrix -LRB- ECM -RRB- 22	3650
the modulation of the extracellular matrix -LRB- ECM -RRB-	3650
the modulation	3650
the extracellular matrix -LRB- ECM -RRB-	3668
the extracellular matrix	3668
ECM	3694
22	3698
Several MMPs , including MMP-2 and -3 ,	3703
Several MMPs	3703
MMP-2 and -3	3727
MMP-2	3727
-3	3737
the ability to degrade CSPGs , which are a type of ECM21	3768
CSPGs , which are a type of ECM21	3791
CSPGs	3791
a type of ECM21	3808
a type	3808
ECM21	3818
Gueye et al.	3826
Gueye	3826
et al.	3832
a detailed report of MMP expression in OECs10 -RRB-	3849
a detailed report	3849
MMP expression	3870
OECs10	3888
the expression of MMP-3	3901
the expression	3901
MMP-3	3919
all five species of CSPGs that inhibit axonal regeneration	3958
all five species	3958
CSPGs that inhibit axonal regeneration	3978
CSPGs	3978
axonal regeneration	3997
OECs	4046
our knowledge	4055
the relevance	4079
MMP expression in OECs	4096
MMP expression	4096
OECs	4114
the degradation of CSPGs , especially neurocan , in injured spinal cord	4123
the degradation of CSPGs	4123
the degradation	4123
CSPGs	4142
injured spinal cord	4173
detail	4223
this study	4234
we	4246
the mRNA expression and protein secretion of MMP-2 , -3 and -9	4259
the mRNA expression and protein secretion	4259
MMP-2 , -3 and -9	4304
MMP-2	4304
-3	4311
-9	4318
rat OECs	4333
we	4347
MMPs	4367
OECs	4409
We	4415
the degradation of neurocan	4433
the degradation	4433
neurocan	4452
the MMPs	4464
the dominant MMPs	4487
OECs	4517
OEC transplantation	4529
SCI model animals	4554
Materials	4574
Methods Animals	4588
Methods	4588
Animals	4596
Thirty-six 8-week-old female Sprague	4605
Thirty-six	4605
8-week-old female Sprague	4616
Dawley -LRB- SD -RRB- rats	4643
Dawley	4643
SD	4651
rats	4655
culture OECs	4673
six 10-week-old female SD rats	4687
the induced SCI model	4732
one 13-week-old SD rat	4759
spinal cord tissue for hematoxylin-eosin -LRB- HE -RRB-	4809
spinal cord tissue	4809
hematoxylin-eosin -LRB- HE -RRB-	4832
hematoxylin-eosin	4832
HE	4851
All animals	4888
barrier cages	4915
a temperature - and humiditycontrolled room with ad libitum access	4932
a temperature - and humiditycontrolled room	4932
ad libitum access	4980
food and water	5001
This study	5017
the Animal Care Committee	5044
the Graduate School of Agricultural and Life Sciences	5073
the Graduate School	5073
Agricultural and Life Sciences	5096
The University of Tokyo -LRB- approval number : P11-523 -RRB-	5128
The University	5128
Tokyo -LRB- approval number : P11-523 -RRB-	5146
Tokyo	5146
approval number : P11-523	5153
approval number	5153
P11-523	5170
Culture of OECs : A total of nine cultures	5180
Culture	5180
OECs : A total of nine cultures	5191
OECs	5191
A total of nine cultures	5197
A total	5197
nine cultures	5208
the following evaluations and transplantation	5235
the following evaluations	5235
transplantation	5265
three of the nine cultures	5282
three	5282
the nine cultures	5291
reverse transcription-polymerase chain reaction -LRB- RT-PCR -RRB-	5323
reverse transcription-polymerase chain reaction	5323
RT-PCR	5372
three cultures	5381
substrate zymography	5410
three cultures	5432
transplantation in SCI model rats	5461
transplantation	5461
SCI model rats	5480
a small portion from five cultures	5500
a small portion	5500
five cultures	5521
the evaluation of the purity of the cultured OECs	5548
the evaluation	5548
the purity of the cultured OECs	5566
the purity	5566
the cultured OECs	5580
the	5580
OECs	5593
Four rats	5599
a time	5628
i.e. , eight olfactory bulbs	5636
i.e.	5636
eight olfactory bulbs	5642
one culture	5687
The methods of OEC culture and purification	5700
The methods	5700
OEC culture and purification	5715
those used in earlier studies , with minor modifications24 ,31	5758
earlier studies	5772
minor modifications24	5794
Eight-week-old SD rats	5821
an intraperitoneal -LRB- i.p. -RRB- injection	5867
pentobarbital -LRB- 50 mg/kg -RRB-	5906
pentobarbital	5906
50 mg/kg	5921
the loss of eyelid reflex	5947
the loss	5947
eyelid reflex	5959
the animals	5974
scarification	6022
the olfactory bulbs	6037
ice-cold Leibovitz L-15 medium -LRB- Invitrogen , Carlsbad , CA , USA -RRB-	6098
ice-cold Leibovitz L-15 medium	6098
Invitrogen	6130
Carlsbad	6142
CA , USA	6152
the remnants of adherent meningeal membranes	6168
the remnants	6168
adherent meningeal membranes	6184
the outer layer of the olfactory bulb	6232
the outer layer	6232
the olfactory bulb	6251
The bulbs	6285
a scalpel blade	6313
0.5 ml	6345
collagenase solution -LRB- 155 U collagenase/mg , Wako , Osaka -RRB- for 20 min	6355
collagenase solution -LRB- 155 U collagenase/mg , Wako , Osaka -RRB-	6355
collagenase solution	6355
155 U collagenase/mg , Wako , Osaka	6377
155 U collagenase/mg	6377
Wako , Osaka	6399
20 min	6416
37 °C in 5 % CO2	6426
37 °C	6426
5 % CO2	6434
0.5 ml of 0.25 % trypsin solution -LRB- Invitrogen -RRB-	6448
0.5 ml	6448
0.25 % trypsin solution -LRB- Invitrogen -RRB-	6458
0.25 % trypsin solution	6458
Invitrogen	6482
the mixture	6509
37 °C for another 15 min	6538
37 °C	6538
another 15 min	6547
incubation	6569
the samples	6581
10 ml of DMEM	6608
10 ml	6608
DMEM	6617
10 % fetal bovine serum -LRB- FBS ; Invitrogen -RRB-	6633
10 % fetal bovine serum	6633
FBS ; Invitrogen	6657
FBS	6657
Invitrogen	6662
1 mM glutamine -LRB- Nissui Pharmaceutical , Tokyo -RRB-	6675
1 mM glutamine	6675
Nissui Pharmaceutical	6691
Tokyo	6714
2 % gentamicin	6726
Sigma	6741
St. Louis	6748
MO , USA	6759
a defined medium -LRB- DM -LRB- + -RRB- -RRB-	6771
a defined medium	6771
DM -LRB- + -RRB-	6789
DM	6789
-LRB- + -RRB-	6792
220 × g	6809
5 min	6821
The pellets	6828
1 ml	6860
soybean trypsin inhibitor	6868
0.25 mg/ml ; Sigma	6895
0.25 mg/ml	6895
Sigma	6907
bovine pancreas DNase	6918
0.04 mg/ml ; Sigma	6941
0.04 mg/ml	6941
Sigma	6953
solution containing bovine serum albumin -LRB- 0.3 mg/ml ; Sigma -RRB-	6960
solution	6960
bovine serum albumin -LRB- 0.3 mg/ml ; Sigma -RRB-	6980
bovine serum albumin	6980
0.3 mg/ml ; Sigma	7002
0.3 mg/ml	7002
Sigma	7013
10 times	7036
a 5-ml glass pipette	7051
21 - and 23 -	7100
21	7100
23	7108
needles with a 1-ml syringe	7118
needles	7118
a 1-ml syringe	7131
The samples	7161
10 ml of DM -LRB- + -RRB- and spun at 220 × g for 5 min	7195
10 ml	7195
DM -LRB- + -RRB- and spun at 220 × g for 5 min	7204
DM	7204
+	7208
220 × g	7223
5 min	7235
The resulting cell pellets	7242
+	7293
containing	7296
2 μM forskolin -LRB- Sigma -RRB-	7307
2 μM forskolin	7307
Sigma	7323
20 ng / ml neuregulin-1 -LRB- R & D Systems , Minneapolis , MN , USA -RRB-	7334
20 ng / ml neuregulin-1	7334
ml neuregulin-1	7341
R & D Systems	7358
R	7358
D Systems	7362
Minneapolis , MN , USA	7373
Minneapolis	7373
MN	7386
USA	7390
a growth medium -LRB- GM -LRB- + -RRB- -RRB-	7398
a growth	7398
medium -LRB- GM -LRB- + -RRB- -RRB-	7407
medium	7407
GM	7415
+	7419
90-mm-dia	7442
dishes at 1 × 106 cells/dish in 10 ml of GM -LRB- + -RRB- for 24 hr .	7453
dishes at 1 ×	7453
dishes	7453
1 ×	7463
106 cells/dish in 10 ml of GM -LRB- + -RRB- for 24 hr	7467
106 cells/dish in 10 ml of GM -LRB- + -RRB- for 24	7467
106 cells/dish	7467
10 ml of GM -LRB- + -RRB- for 24	7485
10 ml	7485
+	7498
for 24	7501
hr	7508
the 24 hrs incubation	7518
the supernatant containing floating cells	7541
the supernatant	7541
floating cells	7568
other dishes	7602
48 hr	7633
this incubation	7646
the supernatant containing floating cells	7663
the supernatant	7663
floating cells	7690
poly-L-lysine-coated dishes and 5 ml of GM -LRB- + -RRB- was added to each dish	7724
poly-L-lysine-coated dishes	7724
5 ml of GM -LRB- + -RRB- was added to each dish	7756
5 ml	7756
GM	7764
+	7768
each dish	7784
Cultures	7795
37 °C in 5 % CO2	7823
37 °C	7823
5 % CO2	7831
10 ml of culture medium	7843
10 ml	7843
culture medium	7852
5 ml of GM -LRB- + -RRB- at 6 days in vitro -LRB- DIV -RRB-	7885
5 ml of GM -LRB- + -RRB- at 6 days in vitro	7885
5 ml	7885
+	7897
at 6	7900
days	7905
DIV	7920
that	7932
the culture medium	7938
every 2-3 days	7969
the culture	7990
confluence	8010
confluence	8037
the cells	8049
RNA extraction , substrate zymography , and transplantation	8073
RNA extraction	8073
substrate zymography	8089
transplantation	8115
SCI model rats	8134
The purity of the cultured OECs	8150
The purity	8150
the cultured OECs	8164
the	8164
OECs	8177
monoclonal mouse anti-p75NTR	8225
1 : 100 ; Millipore , Temecula , CA , USA	8255
1 : 100	8255
Millipore , Temecula , CA , USA	8264
1 : 200 ; Jackson Immunoresearch Laboratories , West Grove , PA , USA	8330
1 : 200	8330
Jackson Immunoresearch Laboratories , West Grove , PA , USA	8339
Jackson Immunoresearch Laboratories	8339
West Grove	8376
PA	8388
USA	8392
The results of immunocytochemistry	8398
The results	8398
immunocytochemistry	8413
a purity of ＞ 95 % -LRB- data not shown -RRB-	8441
a purity	8441
＞ 95 % -LRB- data not shown -RRB-	8453
＞ 95 %	8453
data not shown	8460
data	8460
RT-PCR	8477
We	8485
RT-PCR	8493
the mRNA expressions of MMPs in the OECs	8511
the mRNA expressions	8511
MMPs in the OECs	8535
MMPs	8535
the OECs	8543
the experimental control	8557
the mRNA of HT-1080 , a human fibrosarcoma cell line ,	8583
the mRNA	8583
HT-1080 , a human fibrosarcoma cell line ,	8595
HT-1080	8595
a human fibrosarcoma cell line	8604
RT-PCR	8658
Total RNA	8666
OECs	8695
the RNeasy Mini Kit -LRB- Qiagen , Hilden , Germany -RRB-	8706
the RNeasy Mini Kit	8706
Qiagen	8727
Hilden	8735
Germany	8743
the manufacturer 's protocol	8765
the manufacturer 's	8765
the procedure	8801
genomic DNA	8816
DNase I -LRB- Qiagen -RRB-	8844
cDNA	8865
5 μg of total RNA	8891
5 μg	8891
total RNA	8899
SuperScriptTM III Reverse Transcriptase -LRB- Invitrogen -RRB-	8915
SuperScriptTM III Reverse Transcriptase	8915
Invitrogen	8956
10 mM dNTP Mix -LRB- Invitrogen -RRB-	8972
10 mM dNTP Mix	8972
Invitrogen	8988
The cDNA	9001
specific primers of Mmp2 , Mmp3 , Mmp9 and glyceraldehyde-3	9049
specific primers	9049
Mmp2 , Mmp3 , Mmp9 and glyceraldehyde-3	9069
phosohate dehydrogenase -LRB- Gapdh -RRB-	9108
phosohate dehydrogenase	9108
Gapdh	9133
We	9141
the forward and reverse primers	9153
Mmp2 , Mmp3 , and Mmp9	9189
Primer 3 software	9216
the primer sets for Gapdh given in a previous report were used14	9239
the primer	9239
Gapdh given in a previous report	9259
Gapdh	9259
a previous report	9274
used14	9297
Table 1	9306
The following PCR cycling	9316
94 °C for 2 min	9363
94 °C	9363
2 min	9372
35 cycles of 94 °C for 1 min , 60 °C for 1 min , and 72 °C for 2 min	9389
35 cycles of 94 °C for 1 min	9389
35 cycles	9389
94 °C for 1 min	9402
94 °C	9402
1 min	9411
60 °C for 1 min	9418
60 °C	9418
1 min	9427
72 °C for 2 min	9438
72 °C	9438
2 min	9447
PCR products	9454
0.005 %	9484
ethidium	9491
agarose gels	9515
a Printgraph ® device -LRB- Atto , Tokyo -RRB-	9557
a Printgraph ® device	9557
Atto	9579
Tokyo	9585
Substrate zymography	9593
Substrate zymography	9615
the secretion of MMP-2 , -3 , and -9 from OECs	9660
the secretion	9660
MMP-2 , -3 , and -9 from OECs	9677
MMP-2 , -3 , and -9	9677
OECs	9700
Primary OECs	9706
a poly-L-lysine-coated 60-mm-dia	9738
dish at 2 × 10	9772
dish	9772
2 × 10	9780
6 cells/dish in 6 ml of GM -LRB- + -RRB-	9787
6 cells/dish	9787
6 ml of GM -LRB- + -RRB-	9803
6 ml	9803
GM -LRB- + -RRB-	9811
GM	9811
+	9815
1 DIV	9825
the OECs	9832
+	9865
without FBS -LRB- DM -LRB- - -RRB- -RRB- and then incubated in 6 ml of DM	9868
FBS -LRB- DM -LRB- - -RRB- -RRB- and then	9876
FBS -LRB- DM -LRB- - -RRB- -RRB-	9876
FBS	9876
DM	9881
-	9885
then	9893
incubated	9898
6 ml of DM	9911
6 ml	9911
DM	9919
-	9923
2 μM forskolin -LRB- Sigma -RRB- -LRB- GM -LRB- - -RRB- -RRB-	9937
2 μM forskolin -LRB- Sigma -RRB-	9937
2 μM forskolin	9937
Sigma	9953
GM -LRB- - -RRB-	9961
GM	9961
-LRB- - -RRB-	9964
72 hr	9973
incubation	9986
the culture media	9998
OEC-conditioned media -LRB- OEC-CM -RRB-	10034
OEC-conditioned media	10034
OEC-CM	10057
4 °C , 1000 × g for 10 min	10084
4 °C	10084
1000 × g for 10 min	10089
1000 × g	10089
10 min	10102
floating cells	10119
sodium dodecyl	10155
sulfate-polyacrylamide gel electrophoresis -LRB- SDS-PAGE -RRB-	10170
sulfate-polyacrylamide gel electrophoresis	10170
SDS-PAGE	10214
the OEC-CM	10225
an Amicon ® Ultra Centrifugal Filter Device -LRB- Millipore -RRB-	10268
an Amicon ® Ultra Centrifugal Filter Device	10268
Millipore	10312
an equal volume of OEC-CM	10328
an equal volume	10328
OEC-CM	10347
non-reducing	10371
3 × sample buffer	10384
Equal volumes of samples	10402
Equal volumes	10402
samples	10419
a 7.5 % SDS gel	10445
1 mg/ml gelatin -LRB- Sigma -RRB- for MMP-2 and -9	10471
1 mg/ml gelatin -LRB- Sigma -RRB-	10471
1 mg/ml gelatin	10471
Sigma	10488
MMP-2 and -9	10499
MMP-2	10499
-9	10509
0.5 mg/ml casein -LRB- Sigma -RRB- for MMP-3	10516
0.5 mg/ml casein -LRB- Sigma -RRB-	10516
0.5 mg/ml casein	10516
Sigma	10534
MMP-3	10545
The gels	10552
15 min	10583
10 min on a shaker at room temperature	10604
10 min	10604
a shaker at room temperature	10614
a shaker	10614
room temperature	10626
buffer	10648
2.5 % t-octylphenoxypolyethoxyethanol -LRB- Triton-X ; Sigma -RRB-	10666
2.5 % t-octylphenoxypolyethoxyethanol	10666
Triton-X ; Sigma	10704
Triton-X	10704
Sigma	10714
100 mM Tris-HCl -LRB- pH 7.5 -RRB-	10722
100 mM Tris-HCl	10722
pH 7.5	10739
5 μM ZnCl2	10748
5 mM CaCl2	10764
that	10782
the gels	10788
48 hrs at 37 °C in re-activation buffer	10816
48 hrs	10816
37 °C in re-activation buffer	10826
37 °C	10826
re-activation buffer	10834
100 mM Tris-HCl -LRB- pH 7.5 -RRB- , 5 μM ZnCl2 , and 5 mM CaCl2	10866
100 mM Tris-HCl -LRB- pH 7.5 -RRB-	10866
100 mM Tris-HCl	10866
pH 7.5	10883
5 μM ZnCl2	10892
5 mM CaCl2	10908
incubation	10926
the gels	10938
0.1 % Coomassie Brilliant Blue R-250	10965
0.1 %	10965
a solution of formic acid/methanol/water -LRB- 1 : 30 : 70 -RRB-	11018
a solution	11018
formic acid/methanol/water -LRB- 1 : 30 : 70 -RRB-	11032
formic acid/methanol/water	11032
1 : 30 : 70	11060
1	11060
30 : 70	11064
The presence of MMPs	11074
The presence	11074
MMPs	11090
clear bands	11107
a dark background	11127
we	11150
the co-migration of bands with MMPs	11162
the co-migration	11162
bands with MMPs	11182
bands	11182
MMPs	11193
the conditioned media of rat meningeal fibroblasts -LRB- mFB-CM -RRB-	11203
the conditioned media	11203
rat meningeal fibroblasts -LRB- mFB-CM -RRB-	11228
rat meningeal fibroblasts	11228
mFB-CM	11255
HT-1080 cells	11272
a	11297
molecular weight standard	11307
Bio	11334
Rad Laboratories , Hercules , CA , USA	11339
Rad Laboratories	11339
Hercules	11357
CA	11367
USA	11371
Conditioned media of HT-1080 -LRB- HT-1080-CM -RRB-	11377
Conditioned media of HT-1080	11377
Conditioned media	11377
HT-1080	11398
HT-1080-CM	11407
a positive control for gelatin zymography	11438
a positive control	11438
gelatin zymography	11461
a technical control	11492
Conditioned media from mFBs	11513
Conditioned media	11513
mFBs	11536
a molecular weight control of rat MMP-2 and -9	11554
a molecular weight control	11554
rat MMP-2 and -9	11584
the HT-1080 line	11609
human cells	11647
The gels	11660
a digital scanner	11685
the images of gels	11708
the images	11708
gels	11722
gray-scale	11745
Adobe Photoshop 6.0	11762
Preparation of contusion model	11783
Preparation	11783
contusion model	11798
Ten-week-old SD rats	11815
an i.p. injection of pentobarbital -LRB- 50 mg/kg -RRB-	11859
an i.p. injection	11859
pentobarbital -LRB- 50 mg/kg -RRB-	11880
pentobarbital	11880
50 mg/kg	11895
a dorsal laminectomy	11910
the T10 vertebral level -LRB- Fig. 1A -RRB-	11948
the T10 vertebral level	11948
Fig. 1A	11973
The IH-0400 Impactor	11983
Precision Systems and Instrumentation , Fairfax , VA , USA	12005
Precision Systems	12005
Instrumentation , Fairfax , VA , USA	12027
a severe -LRB- 250 kdyn ; 1dyn ＝ 10 ∧ -5 N -RRB- contusion injury1	12079
250 kdyn ; 1dyn ＝ 10 ∧ -5 N	12089
250 kdyn ; 1dyn ＝ 10 ∧ -5	12089
250 kdyn ; 1dyn ＝	12089
250 kdyn	12089
1dyn	12099
10 ∧ -5	12106
10	12106
-5	12109
N	12112
impact	12141
the overlying muscles	12149
skin opening	12188
The animals	12213
a subcutaneous administration	12234
20 mg/kg cefazolin sodium for the first 3 days post-injury -LRB- dpi -RRB-	12267
20 mg/kg cefazolin sodium for the first 3 days post-injury	12267
20 mg/kg cefazolin sodium for the first 3 days	12267
20 mg/kg cefazolin sodium	12267
the first 3 days	12297
dpi	12327
their bladders	12337
twice a day	12376
a bladder reflex	12394
Transplantation of OECs : OEC transplantation	12425
Transplantation	12425
OECs : OEC transplantation	12444
OECs	12444
OEC transplantation	12450
14-15 dpi	12487
transplantation	12507
OECs	12524
fluorescent labeling	12538
described5	12562
OECs	12575
10 μg/ml	12596
Hoechst 33342 -LRB- Sigma -RRB-	12605
Hoechst 33342	12605
Sigma	12620
DM	12630
+	12633
10 min and then	12640
10 min	12640
then	12651
+	12674
at a density of 5 × 104 cells/μl	12677
at a density of 5 × 104	12677
at	12677
density	12682
5	12693
104	12697
cells/μl	12701
Three of six SCI rats	12711
Three	12711
six SCI rats	12720
OEC suspension -LRB- = the OEC group -RRB-	12752
OEC suspension	12752
= the OEC group	12768
=	12768
the OEC group	12770
the other three	12789
a DM -LRB- + -RRB- injection	12819
+	12824
a negative control -LRB- = the media group -RRB-	12840
a negative control	12840
= the media group	12860
=	12860
the media group	12862
The animals	12880
50 mg/kg , i.p.	12930
50 mg/kg	12930
the T10 level of the spinal cord	12951
the T10 level	12951
the spinal cord	12968
an incision in the dura matter	13013
an incision	13013
the dura matter	13028
the animal	13045
a stereotaxic instrument	13074
rats -LRB- SR-6R ; Narishige Scientific Instrument Laboratory , Tokyo -RRB-	13103
rats	13103
SR-6R ; Narishige Scientific Instrument Laboratory , Tokyo	13109
SR-6R	13109
Narishige Scientific Instrument Laboratory , Tokyo	13116
Narishige Scientific Instrument Laboratory	13116
Tokyo	13160
the points of transplantation	13172
the points	13172
transplantation	13186
a microinjector -LRB- IMS-3 ; Narishige -RRB-	13221
a microinjector	13221
IMS-3 ; Narishige	13238
IMS-3	13238
Narishige	13245
The cell	13257
suspension or DM	13266
+	13283
the injured spinal cord	13304
a 10-μl microsyringe	13334
Hamilton	13356
Reno	13366
NV , USA	13372
a 30-gauge needle	13385
Becton , Dickinson and Co. , Franklin Lakes , NJ , USA	13404
Becton , Dickinson and Co.	13404
Franklin Lakes	13431
NJ	13447
USA	13451
Symmetrical injections about the vein running on the midline of the spinal cord	13457
Symmetrical injections	13457
the vein running on the midline of the spinal cord	13486
the vein	13486
the midline of the spinal cord	13506
the midline	13506
the spinal cord	13521
the lesion epicenter and 1 mm cranial and caudal from the epicenter	13555
the lesion epicenter and 1 mm cranial	13555
the lesion epicenter	13555
1 mm cranial	13580
caudal from the epicenter	13597
caudal	13597
the epicenter	13609
i.e. , a total of six injections	13624
i.e.	13624
a total of six injections	13630
a total	13630
six injections	13641
Fig. 1B	13667
One μl of cell suspension	13677
One μl	13677
cell suspension	13687
each point at 1-mm depth	13723
each point	13723
1-mm depth	13737
the surface of the spinal cord -LRB- Fig. 1C -RRB-	13753
the surface	13753
the spinal cord -LRB- Fig. 1C -RRB-	13768
the spinal cord	13768
Fig. 1C	13785
reflux of the suspension	13804
reflux	13804
the suspension	13814
the injection site	13834
1 min	13854
each injection	13874
the needle	13894
place for another 1 min	13917
place	13917
another 1 min	13927
the injection	13947
transplantation	13982
muscles and skin	13999
the same manner	14031
that used for the preparation of injury	14050
that	14050
the preparation of injury	14064
the preparation	14064
injury	14083
the animals	14095
warmed cages overnight	14134
The administration of antibiotics and manual urination	14158
The administration	14158
antibiotics and manual urination	14180
antibiotics	14180
manual urination	14196
the same manner	14231
that used for the preparation of injury	14250
that	14250
the preparation of injury	14264
the preparation	14264
injury	14283
Tissue staining and immunofluorescence	14291
The animals	14331
7-8 days	14362
transplantation -LRB- 21-22 dpi -RRB-	14377
transplantation	14377
21-22 dpi	14394
the spinal cord tissues	14410
One 13-week-old female SD rat	14449
One	14449
13-week-old female SD rat	14453
intact spinal cord tissue	14509
deep anesthesia by an overdose of pentobarbital -LRB- i.p. -RRB-	14542
deep anesthesia	14542
an overdose of pentobarbital	14561
an overdose	14561
the rats	14598
4 % paraformaldehyde-phosphatebuffered saline -LRB- PFA-PBS -RRB-	14641
4 % paraformaldehyde-phosphatebuffered saline	14641
PFA-PBS	14687
perfusion	14703
the T8-T12 level of the spinal cord	14714
the T8-T12 level	14714
the spinal cord	14734
ice-cold PBS	14790
The meninges	14804
the spinal roots	14844
stereomicroscopic observation	14880
the tissues	14927
further fixed in 4 % PFA-PBS at 4 °C overnight	14944
further	14944
4 % PFA-PBS at 4 °C	14961
4 % PFA-PBS	14961
4 °C	14975
the fixed tissues	14999
PBS solution	15038
20 % -LRB- w/v -RRB- sucrose	15062
w/v	15067
4 °C for more than 6 hr	15083
4 °C	15083
more than 6 hr	15091
Further equilibration	15107
PBS solution	15146
30 % -LRB- w/v -RRB-	15170
30 %	15170
w/v	15175
sucrose for 48 hr	15180
sucrose	15180
48 hr	15192
equilibration	15205
10 mm of spinal cord centered on the lesion epicenter	15220
10 mm	15220
spinal cord centered on the lesion epicenter	15229
spinal cord	15229
the lesion epicenter	15253
a scalpel blade	15287
The tissues	15304
Tissue-Tek ® -LRB- OCT -RRB- compound -LRB- Sakura Finetek Japan , Tokyo -RRB-	15333
Tissue-Tek ® -LRB- OCT -RRB- compound	15333
Tissue-Tek ® -LRB- OCT -RRB-	15333
Tissue-Tek ®	15333
OCT	15346
Sakura Finetek Japan	15361
Tokyo	15383
liquid nitrogen	15412
The frozen blocks	15429
a cryostat -LRB- Leica Microsystems , Tokyo -RRB-	15461
a cryostat	15461
Leica Microsystems , Tokyo	15473
Leica Microsystems	15473
Tokyo	15493
longitudinal horizontal sections of 14 μm thickness	15505
longitudinal horizontal sections	15505
14 μm thickness	15541
three or four sections approx. 560-μm	15562
three or four sections	15562
a glass slide -LRB- MAS-GP ; Matsunami Glass Industries , Osaka -RRB-	15627
a glass slide	15627
MAS-GP ; Matsunami Glass Industries , Osaka	15642
MAS-GP	15642
Matsunami Glass Industries , Osaka	15650
Matsunami Glass Industries	15650
Osaka	15678
Fig. 1D	15686
Several sections	15696
the intact spinal cord and the injured spinal cord of the media group	15716
the intact spinal cord	15716
the injured spinal cord of the media group	15743
the injured spinal cord	15743
the media group	15770
hematoxylin and eosin -LRB- HE -RRB-	15802
hematoxylin and eosin	15802
HE	15825
the degree of injury	15841
the degree	15841
injury	15855
the power of 250 kDyne	15865
the power	15865
250 kDyne	15878
immunofluorescence	15893
the slides	15913
Tris-buffered saline	15941
0.1 %	15973
polyoxyethylene sorbitan monolaurate -LRB- Tween ® 20 ; Sigma -RRB-	15978
polyoxyethylene sorbitan monolaurate	15978
Tween ® 20 ; Sigma	16016
Tween ® 20	16016
Sigma	16027
TBS-T	16035
three times	16042
5 min	16058
each time	16064
normal goat serum -LRB- NGS -RRB- diluted in TBS-T for 1 hr at room temperature	16099
normal goat serum -LRB- NGS -RRB-	16099
normal goat serum	16099
NGS	16118
TBS-T for 1 hr	16134
TBS-T	16134
1 hr	16144
room temperature	16152
The slides	16170
primary antibodies	16206
TBS-T	16236
5 % NGS	16253
4 °C	16263
overnight ; 1	16267
overnight	16267
1	16278
250 polyclonal rabbit anti-MMP-2 -LRB- Abcam , Cambridge , UK -RRB- and 1	16282
250 polyclonal rabbit anti-MMP-2 -LRB- Abcam , Cambridge , UK -RRB-	16282
250 polyclonal rabbit anti-MMP-2	16282
Abcam	16316
Cambridge	16323
UK	16334
1	16342
300 monoclonal mouse anti-neurocan -LRB- Millipore -RRB-	16346
300 monoclonal mouse	16346
anti-neurocan -LRB- Millipore -RRB-	16367
The slides	16394
then washed with TBS-T three times for 5 min each time , and incubated with 1	16410
then	16410
TBS-T three times for 5 min	16427
TBS-T	16427
three times	16433
5 min	16449
each time	16455
1	16485
200 secondary antibodies for 1 hr at room temperature	16489
200 secondary antibodies	16489
1 hr at room temperature	16518
1 hr	16518
room temperature	16526
Cy3-conjugated goat anti-mouse -LRB- Jackson Immunoresearch Laboratories -RRB-	16544
Cy3-conjugated goat anti-mouse	16544
Jackson Immunoresearch Laboratories	16576
FITC-conjugated goat anti-rabbit -LRB- Invitrogen -RRB-	16617
FITC-conjugated goat anti-rabbit	16617
Invitrogen	16651
incubation	16670
the slides	16682
TBS-T three times for 5 min	16710
TBS-T	16710
three times	16716
5 min	16732
each time	16738
Medium	16772
Fluorescent Microscopy -LRB- KPL , Gaithersburg , MD , USA -RRB-	16783
Fluorescent Microscopy	16783
KPL	16807
Gaithersburg	16812
MD , USA	16826
Quantitative analysis of fluorescence-stained images	16836
Quantitative analysis	16836
fluorescence-stained images	16861
the MMP-2 expression and neurocan degradation	16902
the transplantation sites	16955
we	16982
laser	16990
confocal microscopy	17005
We	17026
the degradation of neurocan	17039
the degradation	17039
neurocan	17058
the fluorescent signal intensity of neurocan	17080
the fluorescent signal intensity	17080
neurocan	17116
Fluorescence images of immunostained slides	17126
Fluorescence images	17126
immunostained slides	17149
the FluoView300 laser scanning confocal microscope -LRB- Olympus , Tokyo -RRB-	17194
the FluoView300 laser scanning confocal microscope	17194
Olympus	17246
Tokyo	17255
A 100 × objective lens	17263
the observation of MMP-2	17298
the observation	17298
MMP-2	17317
a 10 × objective lens	17328
a 10 ×	17328
objective lens	17334
neurocan	17362
the camera gain	17377
fixed values for all samples	17411
fixed values	17411
all samples	17428
The region of interest -LRB- ROI -RRB-	17441
The region of interest	17441
The region	17441
interest	17455
ROI	17465
a field	17485
the most intensive accumulation of Hoechst 33342-positive nuclei	17505
the most intensive accumulation	17505
Hoechst 33342-positive nuclei	17540
the MMP-2 secretion	17582
transplanted OECs and neurocan degradation around transplanted OECs	17605
transplanted OECs	17605
neurocan degradation around transplanted OECs	17627
neurocan degradation	17627
transplanted OECs	17655
The ROI in the media group	17674
The ROI	17674
the media group	17685
the counterpart site	17716
The method	17738
neurocan degradation	17765
the digital images was	17791
the digital images	17791
described1	17817
a minor modification	17834
Images of neurocan stained with Cy3	17856
Images	17856
neurocan stained with Cy3	17866
neurocan	17866
Cy3	17888
gray-scale	17910
the mean intensity value -LRB- MIV -RRB- of each image	17926
the mean intensity value -LRB- MIV -RRB-	17926
the mean intensity value	17926
MIV	17952
each image	17960
the histogram of the signal intensity	17991
the histogram	17991
the signal intensity	18008
Image-J software	18035
The results of the quantification	18053
The results	18053
the quantification	18068
means	18104
SD	18112
Statistical analysis	18116
We	18138
Student 's	18146
the MIVs of neurocan expression	18174
the MIVs	18174
neurocan expression	18186
the media and OEC groups	18209
p-values	18239
0.05	18250
Results Table 1 .	18285
Results	18285
Table 1	18293
Primer sequences	18302
RT-PCRa	18323
the mRNA expressions of MMPsb -RRB- in OECsc	18343
the mRNA	18343
expressions of MMPsb -RRB-	18352
expressions	18352
MMPsb	18367
OECsc	18377
Fig. 1	18385
Schema of the protocols .	18393
Schema	18393
the protocols	18403
A : The site of SCI induction .	18418
A : The site of SCI induction	18418
A : The site of SCI	18418
The site of SCI	18421
The site	18421
SCI	18433
induction	18437
Arrow and red circle : the site of impact .	18448
Arrow and red circle	18448
Arrow	18448
red circle	18458
the site of impact	18470
the site	18470
impact	18482
B , C : The sites of OEC transplantation in the injured spinal cord .	18490
B , C	18490
B	18490
C	18493
The sites of OEC transplantation in the injured spinal cord	18496
The sites	18496
OEC transplantation in the injured spinal cord	18509
OEC transplantation	18509
the injured spinal cord	18532
X-marks : The sites of injection .	18557
X-marks	18557
The sites of injection	18566
The sites	18566
injection	18579
D : Sectioning of spinal cord tissue .	18590
D	18590
Sectioning of spinal cord tissue	18593
Sectioning	18593
spinal cord tissue	18607
lines	18634
Sampling point of sections	18641
Sampling point	18641
sections	18659
Fig. 2 .	18670
Fig.	18670
2	18675
OECs	18678
the mRNA of Mmp2 , Mmp3 and Mmp9	18693
the mRNA	18693
Mmp2 , Mmp3 and Mmp9	18705
MMP-2 protein	18738
A : The mRNA expressions of Mmp2 , Mmp3 and Mmp9 in OECs in vitro	18762
: The mRNA expressions of Mmp2 , Mmp3 and Mmp9 in OECs in vitro	18763
The mRNA expressions of Mmp2	18765
The mRNA expressions	18765
Mmp2	18789
Mmp3 and Mmp9 in OECs in vitro	18795
Mmp3 and Mmp9	18795
OECs in vitro	18812
OECs	18812
M : 50 base pair ladder .	18827
M	18827
50 base pair ladder	18830
Lanes 1 and 2 : HT-1080 -LRB- a human fibrosarcoma cell line -RRB- .	18851
Lanes 1 and 2	18851
HT-1080 -LRB- a human fibrosarcoma cell line -RRB-	18866
HT-1080	18866
a human fibrosarcoma cell line	18875
Lanes 3-5 : OECs -LRB- three independent cultures -RRB- .	18908
Lanes 3-5	18908
OECs -LRB- three independent cultures -RRB-	18919
OECs	18919
three independent cultures	18925
B	18954
Gelatinolytic activity of MMP-2	18957
Gelatinolytic activity	18957
MMP-2	18983
-9 in OEC conditioned media -LRB- OEC-CM -RRB-	18993
-9	18993
OEC conditioned media -LRB- OEC-CM -RRB-	18999
OEC	18999
media -LRB- OEC-CM -RRB-	19015
media	19015
OEC-CM	19022
Arrow : MMP-2 .	19031
Arrow	19031
MMP-2	19038
Arrowhead : MMP-9 .	19045
Arrowhead	19045
MMP-9	19056
M : molecular weight standard .	19063
M	19063
molecular weight standard	19066
Lanes 1 and 2 : OEC-CM .	19093
Lanes 1 and 2	19093
OEC-CM	19108
Lane 3 : Rat meningeal fibroblast conditioned media -LRB- mFB-CM -RRB- .	19116
Lane 3	19116
Rat meningeal fibroblast conditioned media -LRB- mFB-CM -RRB-	19124
Rat meningeal fibroblast	19124
media -LRB- mFB-CM -RRB-	19161
media	19161
mFB-CM	19168
Lane 4 : HT-1080 conditioned media -LRB- HT-1080-CM -RRB- .	19177
Lane 4	19177
HT-1080 conditioned media -LRB- HT-1080-CM -RRB-	19185
HT-1080	19185
media -LRB- HT-1080-CM -RRB-	19205
media	19205
HT-1080-CM	19212
Lane 3	19225
a molecular weight control of rat MMP-2 and -9	19244
a molecular weight control	19244
rat MMP-2 and -9	19274
rat MMP-2	19274
-9	19288
Lane 4	19296
an experimental control	19315
Fig. 3 .	19341
Fig.	19341
3	19346
Hematoxylin and eosin	19349
staining of the intact -LRB- A -RRB-	19371
staining	19371
the intact -LRB- A -RRB-	19383
injured spinal cord in the media group -LRB- B -RRB-	19402
injured spinal cord	19402
the media group -LRB- B -RRB-	19425
the media group	19425
B	19442
gm : gray matter .	19446
gm	19446
gray matter	19450
wm : white matter .	19463
wm	19463
white matter	19467
T : thorasic cord .	19481
T	19481
thorasic cord	19484
lc : lesion cavity .	19499
lc	19499
lesion cavity	19503
Arrows : lesion epicenter .	19518
Arrows	19518
lesion epicenter	19526
Bar	19544
1 mm	19550
Fig. 4 .	19557
Fig.	19557
4	19562
Immunofluorescence	19565
MMP-2	19587
the intact spinal cord -LRB- A-C -RRB-	19596
the intact spinal cord	19596
A-C	19620
the media -LRB- D-F -RRB- and OEC -LRB- G-I -RRB-	19632
the media	19632
D-F	19643
OEC	19652
G-I	19657
groups	19662
gm : gray matter .	19670
gm	19670
gray matter	19674
wm : white matter .	19687
wm	19687
white matter	19691
Red : Hoechst 33342 .	19705
Red	19705
Hoechst 33342	19710
Green : MMP-2 .	19725
Green	19725
MMP-2	19732
Bar	19739
20 μm	19745
Fig. 5 .	19753
Fig.	19753
5	19758
Immunofluorescence	19761
neurocan and the quantification	19783
neurocan	19783
the quantification	19796
fluorescent signals	19818
neurocan	19841
A-C	19851
Immunofluorescence	19856
neurocan in the intact -LRB- A -RRB- , media group -LRB- B -RRB-	19878
neurocan	19878
the intact -LRB- A -RRB- , media group -LRB- B -RRB-	19890
the intact -LRB- A -RRB- , media group	19890
-LRB- A -RRB- , media	19901
-LRB- A -RRB-	19901
media	19906
B	19919
OEC group -LRB- C -RRB-	19927
OEC group	19927
C	19937
gm : gray matter .	19941
gm	19941
gray matter	19945
wm : white matter .	19958
wm	19958
white matter	19962
Red : neurocan .	19976
Red	19976
neurocan	19981
Blue : Hoechst 33342 .	19991
Blue	19991
Hoechst 33342	19997
Bar	20012
200 μm	20018
D	20026
Quantification of fluorescent signals of neurocan in the media and OEC groups	20029
Quantification	20029
fluorescent signals of neurocan in the media and OEC groups	20047
fluorescent signals	20047
neurocan in the media and OEC groups	20070
neurocan	20070
the media and OEC groups	20082
Vertical bars : SD .	20108
Vertical bars	20108
SD	20123
mRNA expression	20128
MMPs in cultured OECs The mRNA expressions of Mmp2 , Mmp3 and Mmp9	20147
MMPs	20147
OECs	20164
The mRNA expressions of Mmp2 , Mmp3 and Mmp9	20169
The mRNA expressions	20169
Mmp2 , Mmp3 and Mmp9	20193
OECs -LRB- Fig. 2A -RRB-	20239
OECs	20239
Fig. 2A	20245
No significant difference	20255
three independent OEC cultures in each mRNA expression	20302
three independent OEC cultures	20302
each mRNA expression	20336
Secretion of MMPs from cultured OECs The results of the gelatin zymography	20358
Secretion	20358
MMPs from cultured OECs The results of the gelatin zymography	20371
MMPs	20371
OECs	20390
The results of the gelatin zymography	20395
The results	20395
the gelatin zymography	20410
MMP-2 -LRB- 68 kD -RRB-	20448
MMP-2	20448
68 kD	20455
the OEC-CM	20479
MMP-9 -LRB- 92 kD -RRB-	20499
MMP-9	20499
92 kD	20506
Fig. 2B	20531
MMP-3	20541
the OEC-CM	20567
casein zymography -LRB- data not shown -RRB-	20581
casein zymography	20581
data not shown	20600
data	20600
Evaluation of	20617
Evaluation	20617
SCI	20639
HE	20646
the intact rat	20661
spinal cord , gray matter , which was stained strongly by hematoxylin and eosin	20676
spinal cord	20676
gray matter	20689
hematoxylin and eosin	20732
white matter , whose staining was faint ,	20759
white matter	20759
staining	20779
Fig. 3A	20829
the induced SCI/injured spinal cord	20842
the typical structure of gray matter and white matter	20879
the typical structure	20879
gray matter and white matter	20904
gray matter	20904
white matter	20920
the area of the lesion epicenter	20954
the area	20954
the lesion epicenter	20966
a large cavity across the T9-T10 spinal level	20988
a large cavity	20988
the T9-T10 spinal level	21010
eosinophilic cells	21050
the cavity -LRB- Fig. 3B -RRB-	21085
the cavity	21085
Fig. 3B	21097
There	21107
no tissue sections	21118
normal structure of spinal cord among the induced SCI animals	21153
normal structure	21153
spinal cord among the induced SCI animals	21173
spinal cord	21173
the induced SCI animals	21191
the injury	21232
the power	21251
250 kDyne spread at least 5 mm cranial and caudal from the point of impact	21264
250 kDyne spread at least 5 mm cranial	21264
250 kDyne spread	21264
at least 5 mm cranial	21281
caudal from the point of impact	21307
caudal	21307
the point of impact	21319
the point	21319
impact	21332
Expression	21340
MMP-2	21354
OECs	21363
injured spinal cord	21384
intact spinal cord	21407
the expression of MMP-2	21427
the expression	21427
MMP-2	21445
the area of gray matter -LRB- Fig. 4A-C -RRB-	21466
the area	21466
gray matter -LRB- Fig. 4A-C -RRB-	21478
gray matter	21478
Fig. 4A-C	21491
the media group	21506
the structure consisting of gray matter and white matter	21523
the structure	21523
gray matter and white matter	21551
gray matter	21551
white matter	21567
only a weak expression of MMP-2	21599
only a weak expression	21599
MMP-2	21625
Fig. 4D-F	21645
the OEC group	21660
MMP-2	21684
injured spinal cord	21719
the expression of MMP-2	21744
the expression	21744
MMP-2	21762
Hoechst 33342	21788
Hoechst	21788
positive nuclei -LRB- Fig. 4G-I -RRB-	21803
positive nuclei	21803
Fig. 4G-I	21820
Fluorescent intensity of neurocan	21832
Fluorescent intensity	21832
neurocan	21857
the intact spinal cords , neurocan expression	21869
spinal cords , neurocan	21880
spinal cords	21880
neurocan	21894
gray matter	21935
faint or no expression	21948
white matter -LRB- Fig. 5A -RRB-	21987
white matter	21987
Fig. 5A	22001
the injured spinal cords	22014
neurocan	22040
the area of remaining tissue -LRB- Fig. 5B -RRB-	22073
the area	22073
remaining tissue -LRB- Fig. 5B -RRB-	22085
remaining tissue	22085
Fig. 5B	22103
The evaluation of immunofluorescent intensity	22113
The evaluation	22113
immunofluorescent intensity	22131
only the media group -LRB- B -RRB- and the OEC group	22181
the media group -LRB- B -RRB-	22186
the media group	22186
B	22203
the OEC group	22210
C	22225
the intact spinal cords	22236
a structure and staining pattern	22264
those of the injured spinal cord	22330
those	22330
the injured spinal cord	22339
The immunoreactivity of neurocan in the OEC group	22364
The immunoreactivity	22364
neurocan in the OEC group	22388
neurocan	22388
the OEC group	22400
that in the media group -LRB- Fig. 5B , C -RRB-	22430
that	22430
the media group -LRB- Fig. 5B , C -RRB-	22438
the media group	22438
Fig. 5B , C	22455
Fig. 5B	22455
C	22464
The quantification of immunoreactivity	22468
The quantification	22468
immunoreactivity	22490
a significant decrease of neurocan expression	22517
a significant decrease	22517
neurocan expression	22543
the OEC group	22566
MIVs : 38.48 ± 3.26 in the media group vs. 28.69 ± 1.10 in the OEC group	22581
MIVs : 38.48 ± 3.26 in the media group vs. 28.69 ± 1.10	22581
MIVs	22581
38.48	22587
3.26 in the media group vs. 28.69	22595
3.26	22595
the media group vs. 28.69	22603
the media group	22603
28.69	22623
± 1.10	22629
the OEC group	22639
p 0 0.047 , Fig. 5D	22654
p	22654
0 0.047	22656
Fig. 5D	22665
Discussion The RT-PCR results	22676
Discussion	22676
The RT-PCR	22687
the cultured OECs	22718
the	22718
OECs	22731
mRNA of Mmp2 , Mmp3 and Mmp9	22746
mRNA	22746
Mmp2 , Mmp3 and Mmp9	22754
our knowledge	22778
this	22793
the first study reporting the mRNA expression of Mmp3 in cultured OECs	22801
the first study	22801
the mRNA expression of Mmp3	22827
the mRNA expression	22827
Mmp3	22850
OECs	22867
Our substrate zymography results	22873
the	22918
OECs	22931
MMP-2	22945
culture supernatants	22956
MMP-3 and -9	22986
MMP-3	22986
-9	22996
the OEC-CM	23020
These findings	23032
OECs	23060
MMP-2	23075
MMP-3 and -9	23102
MMP-3	23102
-9	23112
the mRNA expression of Mmp3 and Mmp9 in cultured OECs	23124
the mRNA expression	23124
Mmp3 and Mmp9 in cultured OECs	23147
Mmp3 and Mmp9	23147
OECs	23173
protein expression	23211
earlier studies	23240
MMP-9 secretion	23265
OECs	23284
their results	23290
a weaker expression of MMP-9 protein	23316
a weaker expression	23316
MMP-9 protein	23339
that of MMP-210,26	23365
that	23365
MMP-210,26	23373
the results of substrate zymography	23389
the results	23389
substrate zymography	23404
MMP-2	23440
the major MMP secreted by OECs	23450
the major MMP	23450
OECs	23476
we	23482
the relevance of MMP-2 secretion	23495
the relevance	23495
MMP-2 secretion	23512
OECs and the degradation of neurocan in a rat injured spinal cord model	23531
OECs	23531
the degradation of neurocan in a rat injured spinal cord model	23540
the degradation	23540
neurocan in a rat injured spinal cord model	23559
neurocan	23559
a rat injured spinal cord model	23571
a rat	23571
spinal cord model	23585
An intense immunofluorescent signal	23604
MMP-2 in the OEC group associated with Hoechst 33342-positive nuclei	23643
MMP-2	23643
the OEC group associated with Hoechst 33342-positive nuclei	23652
the OEC group	23652
Hoechst 33342-positive nuclei	23682
We	23726
this finding	23743
the transplanted OECs	23770
MMP-2 in the injured spinal cord	23801
MMP-2	23801
the injured spinal cord	23810
there	23844
a direct verification	23858
the transplanted OECs	23885
MMP-2	23916
there	23926
a possibility	23936
cells	23955
the transplanted OECs or parenchymal cells of spinal cord secreted MMP-2	23972
the transplanted OECs	23972
parenchymal cells of spinal cord secreted MMP-2	23997
parenchymal cells	23997
spinal cord secreted MMP-2	24018
spinal cord	24018
MMP-2	24039
our	24046
investigation	24059
the ability	24080
OECs to secrete MMP-2	24095
MMP-2	24111
an earlier study also suggested that OECs in vivo situation secrete MMP-210	24122
an earlier study	24122
OECs	24159
situation	24172
MMP-210	24190
The above-cited study by Pastrana et al.	24200
The above-cited study	24200
Pastrana et al.	24225
Pastrana	24225
et al.	24234
an immortalized cell line of OECs	24253
an	24253
cell line of OECs	24269
cell line	24269
OECs	24282
the ability to secrete MMP-2 in injured spinal cord26	24292
MMP-2	24315
injured spinal cord26	24324
We	24348
the intense expression of MMP-2 associated with Hoechst 33342-positive nuclei	24375
the intense expression	24375
MMP-2 associated with Hoechst 33342-positive nuclei	24401
MMP-2	24401
Hoechst 33342-positive nuclei	24423
the secretion of MMP-2	24463
the secretion	24463
MMP-2	24480
transplanted OECs	24491
addition	24513
the immunofluorescent signal of neurocan	24523
the immunofluorescent signal	24523
neurocan	24555
the present study 's OEC group	24595
the present study 's	24595
we	24630
this result	24646
neurocan	24673
the transplantation of OECs	24699
the transplantation	24699
OECs	24722
Neurocan	24728
reactive astrocytes in injured spinal cord1	24774
reactive astrocytes	24774
injured spinal cord1	24797
it	24829
cells	24867
neurocan	24883
our immunofluorescence results	24895
the transplanted OECs	24945
neurocan	24983
We	24993
the expression of neurocan	25011
the expression	25011
neurocan	25029
the transplanted OECs	25074
neurocan	25106
a significant level	25118
there	25148
a possibility	25164
the transplanted OECs	25183
neurocan	25215
an insignificant level	25227
we	25251
the significant decrease of neurocan by OEC transplantation	25270
the significant decrease	25270
neurocan by OEC transplantation	25298
neurocan	25298
OEC transplantation	25310
a larger sense	25334
the possibility of OECs expressing neurocan at an insignificant level	25354
the possibility	25354
OECs expressing neurocan at an insignificant level	25373
OECs	25373
neurocan	25389
an insignificant level	25401
our findings	25441
OECs	25459
MMP-2 in injured spinal cord	25473
MMP-2	25473
injured spinal cord	25482
neurocan	25511
the transplantation of OECs	25537
the transplantation	25537
OECs	25560
us	25569
this decrease in neurocan	25589
this decrease	25589
neurocan	25606
the degradation of neurocan	25635
the degradation	25635
neurocan	25654
MMP-2 secreted from transplanted OECs	25666
MMP-2	25666
transplanted OECs	25686
this study	25714
several limitations	25729
the lack	25760
an investigation	25772
the effect	25792
OECs	25806
other species of CSPGs	25814
other species	25814
CSPGs	25831
the lack	25841
an evaluation	25853
the effects of OECs on axonal regeneration or locomotor function	25870
the effects	25870
OECs on axonal regeneration or locomotor function	25885
OECs	25885
axonal regeneration or locomotor function	25893
our results	25936
a new property of OECs in vitro and in injured spinal cord	25958
a new property	25958
OECs in vitro and in injured spinal cord	25976
OECs	25976
injured spinal cord	25997
Further investigation	26018
the properties of OECs	26073
the properties	26073
OECs	26091
OEC transplantation	26113
a treatment for severe SCI	26136
a treatment	26136
severe SCI	26152
